Treatments for acute bipolar depression: Meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics

Pharmacopsychiatry

Volumn 47, Issue 2, 2014, Pages 43-52

  Selle, V ^a,b   Schalkwijk, S ^a,c   Vazquez G H ^a,d   Baldessarini, R J ^a,e  

^a MCLEAN HOSPITAL   (United States)

^b Viarnetto Psychiatric Clinic   (Switzerland)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF PALERMO   (Argentina)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

anticonvulsants; antipsychotics; bipolar depression; controlled trials; lithium; meta analysis

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; FLUOXETINE; LAMOTRIGINE; LITHIUM; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; VALPROIC ACID; ZIPRASIDONE;

ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; DRUG EFFICACY; DRUG RESPONSE; HUMAN; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SYSTEMATIC REVIEW;

ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; HUMANS; LITHIUM CHLORIDE;

EID: 84898597835     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0033-1363258     Document Type: Article

References (66)

1. Baldessarini R. J., Vieta E., Calabrese J. R. et al. Bipolar depression: overview and commentary. Harv Rev Psychiatry: 2010; 18 143 157
2. Baldessarini R. J. Chemotherapy in Psychiatry. third edition New York Springer Press: 2013
3. Baldessarini R. J., Salvatore P., Khalsa H-MK et al. Morbidity in 303 first-episode bipolar I disorder patients. Bipolar Disord: 2010; 12 264 270
4. Fountoulakis K. N., Kasper S., Andreasen O. et al. Efficacy of pharmacotherapy in bipolar disorder: report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci: 2012; 262 Suppl 1 1 48
5. Malhi G. S., Bargh D. M., McIntyre R. et al. Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. Bipolar Disord: 2012; 14 Suppl 1 1 21
6. Samalin L., Llorca P. M. Methodological approach to inter guideline variability in the management of bipolar disorders (French). Encephale: 2012; 38 126 132
7. Yatham L. N., Kennedy S. H., Parikh S. V. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of guidelines for management of patients with bipolar disorder: 2013. Bipolar Disord: 2013; 15 1 44
8. Cruz N., Sanchez-Moreno J. H., Torres F. et al. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: meta-analysis. Int J Neuropsychopharmacol: 2010; 13 5 14
9. Vieta E., Locklear J., Günther O. et al. Treatment options for bipolar depression: systematic review of randomized, controlled trials. J Clin Psychopharmacol: 2010; 30 579 590
10. Kemp D. E., Ganocy S. J., Brecher M. et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord: 2011; 130 171 179
11. Cerullo M. A., Strakowski S. M. Systematic review of the evidence for the treatment of acute depression in bipolar I disorder. CNS Sprectr: 2013; 18 199 208
12. Reinares M., Rosa A. R., Franco C. et al. Systematic review on the role of anticonvulsants in the treatment of acute bipolar depression. Int J Neuropsychopharmacol: 2013; 16 485 496
13. Tondo L., Baldessarini R. J., Vázquez G. et al. Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders. Acta Psychiatr Scand: 2013; 127 355 364
14. Vázquez G. H., Tondo L., Undurraga J. et al. Overview of antidepressant treatment in bipolar depression. Intl J Neuropsychopharmacol: 2013; 22 1 13
15. Moher D., Hopewell S., Schulz K. F. et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomized trials. BMJ: 2010; 340 c869
16. Furukawa T. A., Barbui C., Cipriani A. et al. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol: 2006; 59 7 10
17. Calabrese J. R., Bowden V. L., Sachs G. S. et al. Double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar-I depression. J Clin Psychiatry: 1999; 60 79 88
18. Tohen M., Vieta E., Calabrese J. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry: 2003; 60 1079 1088
19. Calabrese J. R., Keck P. E., Macfadden W. Randomized, double-blind, placebo controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry: 2005; 162 1351 1360
20. Davis L. L., Bartolucci A., Perry F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord: 2005; 85 259 266
21. Thase M. E., Macfadden W., Weisler R. H. Efficacy of quietapine monotherapy in bipolar I and II depression: double-blind, placebo-controlled (BOLDER II) study. J Clin Psychopharmacol: 2006; 26 600 609
22. Ghaemi S. N., Gilmer W. S., Goldberg J. F. et al. Divalproex in the treatment of acute bipolar depression: preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry: 2007; 68 1840 1844
23. Zhang Z. J., Kang W. H., Tan Q. R. et al. Adjunctive herbal medicine with carbamazepine for bipolar disorders: double-blind, randomized, placebo-controlled study. J Psychiatr Res: 2007; 41 360 369
24. Thase M. E., Jonas A., Khan A. Aripiprazole monotherapy in non-psychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol: 2008; 28 13 20
25. McElroy S. L., Richard H. W., Chang W. Double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry: 2010; 71 163 174
26. Suppes T., Datto C., Minkwitz M. et al. Effectiveness of the extended release formulation of quetiapine monotherapy for the treatment of acute bipolar depression. J Affect Disord: 2010; 121 106 115
27. Young A. H., McElroy S. L., Bauer M. Double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry: 2010; 71 150 162
28. Muzina D. J., Gao K., Kemp D. E. et al. Acute efficacy of divalproex-sodium vs. placebo in mood stabilizer-naive bipolar I or II depression: double-blind, randomized, placebo-controlled trial. J Clin Psychiatry: 2011; 72 813 819
29. Lombardo I., Sachs G., Kolluri S. et al. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J Clin Psychopharmacol: 2012; 32 470 478
30. Tohen M., McDonnell D. P., Case M. et al. Randomized, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry: 2012; 201 376 382
31. Loebel A., Cucchiaro J., Silva R. et al. Lurasidone monotherapy in the treatment of bipolar I Depression: randomized, double-blind, placebo-controlled study. Am J Psychiatry: 2013; Epub ahead of print (30 Oct)
32. Glaxo-SmithKline Corporation Multicenter, double-blind, placebo-controlled, flexible dose (100-400 mg) 10 week evaluation of the safety and efficacy of Lamictal (lamotrigine) in the treatment of a major depressive episode in patients with bipolar disorder (summary report of trial SCAA2010, updated 2005, 5 pp). Accessible at: http://www.gsk-clinicalstudyregister.com/ result-detail.jsp?protocolId=SCAA2010&studyId=6FEAE60A-D3CE-4B66-9881- 0EB17D60632B&compound=lamotrigine (accessed 1 March 2013)
33. Glaxo-SmithKline Corporation Multicenter, double-blind, placebo-controlled, fixed dose evaluation of the safety, efficacy and tolerability of Lamictal (lamotrigine) in the treatment of a major depressive episode in patients with type I bipolar disorder (summary report of trial SCA40910, updated 2005, 6 pp). Accessible at: http://www.gsk- clinicalstudyregister.com/result-detail.jsp?protocolId=SCA40910&studyId= 08FF5601-AD4E-4D59-B8AA-652E9448555A&compound=lamotrigine (accessed 1 March 2013)
34. Goldsmith D. R., Wagstaff A. J., Ibbotson T. et al. Lamotrigine: review of its use in bipolar disorder. Drugs: 2003; 63 2029 2050
35. Calabrese J. R., Huffman R. F., White R. L. et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord: 2008; 10 323 333
36. Geddes J. R., Calabrese J. R., Goodwin G. M. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomized trials. Br J Psychiatry: 2009; 194 4 9
37. Bond D. J., Lam R. W., Yatham L. N. Divalproex sodium vs. placebo in the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord: 2010; 124 228 234
38. Smith L. A., Cornelius V. R., Azorin J. M. et al. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord: 2010; 122 1 9
39. Brown E. B., McElroy S. L., Keck P. E. Jr et al. Seven-week, randomized, double-blind trial of olanzapine/fluoxetine combination vs. lamotrigine in the treatment of bipolar-I depression. J Clin Psychiatry: 2006; 67 1025 1033
40. Schaffer A., Zuker P., Levitt A. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord: 2006; 96 95 99
41. Van der Loos M. L., Mulder P. G., Hartong E. G. et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry: 2009; 70 223 231
42. Mendels J. Lithium in the treatment of depression. Am J Psychiatry: 1976; 133 373 378
43. Zornberg G. L., Pope H. G. Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol: 1993; 13 397 408
44. Bhagwagar Z., Goodwin G. M. Role of lithium in the treatment of bipolar depression. Clin Neurosci Res: 2002; 2 222 227
45. Yatham L. N., Calabrese J. R., Kusumakar V. Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord: 2003; 5 85 97
46. Goodwin F. K., Murphy D. L., Bunney W. E. Lithium carbonate treatment in depression and mania. Arch Gen Psychiatry: 1969; 21 486 496
47. Stokes P. E., Stoll P. M., Shamoian C. A. et al. Efficacy of lithium as acute treatment of manic-depressive illness. Lancet: 1971; 1 1319 1325
48. Goodwin R. K., Murphy D. L., Dunner D. L. et al. Lithium response in unipolar vs. bipolar depression. Am J Psychiatry: 1972; 129 76 79
49. Noyes R. Jr, Dempsey G. M. Lithium treatment of depression. Compr Psychiatry: 1974; 15 187 193
50. Donnelly E. F., Goodwin F. K., Waldman I. N. et al. Prediction of antidepressant responses to lithium. Am J Psychiatry: 1978; 135 552 556
51. Ballenger J. C., Post R. M. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry: 1980; 137 782 790
52. Post R. M., Uhde T. W., Roy-Byrne P. P. et al. Antidepressant effects of carbamazepine. Am J Psychiatry: 1986; 143 29 34
53. McIntyre R. S., Mancini D. A., McCann S. et al. Topiramate vs. bupropion-SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: preliminary single-blind study. Bipolar Disord: 2002; 4 207 213
54. Saricicek A., Maloney K., Muralidharan A. et al. Levetiracetam in management of bipolar depression: randomized, double-blind, placebo-controlled trial. J Clin Psychiatry: 2011; 72 744 750
55. McElroy S. L., Suppes T., Frye M. et al. Open-label aripiprazole in the treatment of acute bipolar depression: prospective pilot trial. J Affect Disord: 2007; 101 275 281
56. Ketter A. T., Wang P. W., Chandker R. A. et al. Adjunctive aripiprazole in treatment resistant bipolar depression. Ann Clin Psychiatry: 2006; 18 169 172
57. Shelton R. C., Stahl S. M. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry: 2004; 65 1715 1719
58. Pacchiarotti I., Bond D. J., Baldessarini R. J. et al. International Society for Bipolar Disorders (ISBD) task-force report on antidepressant use in bipolar disorders. Am J Psychiatry: 2013; in press
59. Centorrino F., Masters G., Baldessarini R. J. et al. Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. Hum Psychopharmacol: 2012; 27 521 526
60. Baldessarini R. J., Henk H. J., Sklar A. R. et al. Psychotropic medications for bipolar disorder patients in the United States: polytherapy and adherence. Psychiatr Serv: 2008; 59 1175 1183
61. Vieta E., Langosch J. M., Figueira M. L. et al. Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd). Int J Neuropsychopharmacol: 2013; 13 1 14
62. Undurraga J., Baldessarini R. J. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology: 2012; 37 851 864
63. Lorenzo L. S., Vázquez G. H., Zaratiegui R. M. et al. Characteristics of bipolar disorder patients given antidepressants. Hum Psychopharmacol: 2012; 27 486 491
64. Undurraga K., Baldessarini R. J., Valenti M. et al. Bipolar depression: clinical correlates of receiving antidepressants. J Affect Disord: 2012; 139 89 93
65. Tondo L., Vázquez G. H., Baldessarini R. J. Mania associated with antidepressant-treatment: comprehensive meta-analytic review. Acta Psychiatr Scand: 2010; 121 404 414
66. Turner E. H., Matthews A. M., Linardatos E. et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med: 2008; 358 252 260